Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 316

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 316
---
 of business 159 Profusa meets many of the criteria listed above, including its ability to generate revenue from the Lumee Oxygen product in Europe without further regulatory approval and the potential to generate revenue from Lumee Oxygen product in the U.S. and the Lumee Glucose product in both Europe and the U.S. following regulatory approval, its growth plan to be a leading digital health technology company, its experienced management team, its clinically important consumer -friendlyplatform, its private independent structure, and its potential domestic and international base of business. More specifically, the NorthView Board took into consideration the following factors or made the following determinations, as applicable: (i) A target company in the health care sector with near term revenue potential: Profusa’s biosensor technology and developed applications have been validated and O2 approved in EU while seeking FDA approval in US. Thus, near -termrevenue potential, subject to regulatory approval. (ii) High growth prospects:In addition to oxygen and glucose monitoring, Profusa’s biosensor technology and AI monitoring is a true platform with meaningful revenue growth prospects. The Lumee Oxygen product is ready to be launched in the EU without further regulatory approval. (iii) Proven and experienced management team that is positioned to successively lead New Profusa after the Merge:Profusa is led by Ben Hwang, PhD and co -founder. Ben has a team that has been working effectively together for more than nine years. (iv) Technology that is more than a single application and has the potential to be a platform:The Profusa biosensor platform is clinically important, consumer -friendlyplatform which measures an individual’s biochemistry that is easy to use, cost -effective, and provides the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users while collecting actionable data potentially for clinical trial and pharmaceutical development. Additional product applications include lactate, sodium, CO 2and ethanol monitoring (v) Ready to go public with a substantial infrastructure and with minimal cash needs to meet milestones:Profusa is based in the U.S. with global prospects and investor interest. Profusa plans to manage operations the U.S. while manufacturing with contractors or partners regionally. (vi) Strong Investor Support:Profusa has raised over $70 million in capital to date in the private markets and over $30 million in non -dilutivefunding by DARPA and NIH demonstrating broad based interest. Strategic, global investors and potential partners have also demonstrated interest in providing financial support.